e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Molecular markers: diagnosis and management of malignant pleural effusions
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Endogenous thrombin potential (ETP) in pleural effusions
L. Teixeira, M. Colombini, F. Vargas, M. Acencio, R. Siqueira, C. Silva, V. Alvarenga, L. Antonangelo (São Paulo, Brazil)
Source:
Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions
Session:
Molecular markers: diagnosis and management of malignant pleural effusions
Session type:
Poster Discussion
Number:
3545
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Teixeira, M. Colombini, F. Vargas, M. Acencio, R. Siqueira, C. Silva, V. Alvarenga, L. Antonangelo (São Paulo, Brazil). Endogenous thrombin potential (ETP) in pleural effusions. Eur Respir J 2011; 38: Suppl. 55, 3545
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Interelukin-17A is elevated in parapneumonic pleural effusions and is associated with neutrophils and VEGF
Source: Eur Respir J 2006; 28: Suppl. 50, 551s
Year: 2006
Intrapleural fibrinolysis modulation in malignant pleural effusions
Source: Eur Respir J 2001; 18: Suppl. 33, 517s
Year: 2001
Effectiveness and safety of tissue plasminogen activators (t-PA) in complicated pleural effusion (CPE), what the correlation with time it stays in the pleural space?
Source: Annual Congress 2013 –A modern approach to lung diseases: from bronchi to pleura
Year: 2013
The profile of neutrophils and D-dimer in pleural fluid is useful to monitor the pleurodesis process after talc poudrage in malignant pleural effusions (MPE)
Source: Eur Respir J 2002; 20: Suppl. 38, 70s
Year: 2002
Tumour marker (TM) CA 19-9 in pleural fluid at patients with malignant and paramalignant pleural effusion (PE)
Source: Eur Respir J 2001; 18: Suppl. 33, 387s
Year: 2001
Measurement of pleural fluid lactate dehydrogenase and adenosine deaminase for distinguishing malignant pleural effusions and other exudative pleural effusions
Source: Eur Respir J 2004; 24: Suppl. 48, 246s
Year: 2004
Diagnostic implications of telomerase activity in pleural effusions
Source: Eur Respir J 2003; 22: 422-426
Year: 2003
Role of adenosine deaminase (ADA) in differentiating tuberculous pleural effusions
Source: Eur Respir J 2004; 24: Suppl. 48, 644s
Year: 2004
Role of pleural irrigation with normal saline versus streptokinase in complicated pleural effusions.
Source: International Congress 2019 – Interventional pulmonology: current pleural practice
Year: 2019
Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusions
Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions
Year: 2012
Talc mediates angiostasis in malignant pleural effusions via endostatin induction
Source: Eur Respir J 2007; 29: 761-769
Year: 2007
Interleukin-8 and other mediators are related to tumour burden in malignant pleural effusions (MPE)
Source: Eur Respir J 2007; 30: Suppl. 51, 103s
Year: 2007
Value of pleural fluid and serum NT-ProBNP levels in differentiation of transudative and exudative pleural effusions
Source: Annual Congress 2010 - Novel approach in diagnosis and treatment of pleural effusions
Year: 2010
Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma
Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions
Year: 2012
Interleukin-16 in tuberculous and malignant pleural effusions
Source: Eur Respir J 2005; 25: 605-611
Year: 2005
Usefulness of pleural fluid C-reactive protein in differentiation of pleural effusions
Source: Annual Congress 2010 - From rare towards common lung diseases: diagnostic and monitoring challenges
Year: 2010
Usefulness of pleural fluid C-reactive protein in differentiation of pleural effusions
Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience
Year: 2009
Pleural NT-PROBNP and albumin gradient (serum-pleural levels difference) in patients with exudative pleural effusion (PE) and previous diuretic therapy
Source: Annual Congress 2009 - Pulmonary embolism and cardiovascular diseases
Year: 2009
Utility of significant number of mesothelial cells in tuberculous pleural effusions
Source: Eur Respir J 2004; 24: Suppl. 48, 426s
Year: 2004
Pentraxin-3: A novel biomarker for the differentiation of parapneumonic effusion and malignant pleural effusion
Source: Annual Congress 2012 - Novelties in clinical management of thoracic diseases: from diaphragm to pleura
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept